Good news: Puli Pharmaceutical has been honored as a member of the National Biomedical Enterprise Pl

Good news: Puli Pharmaceutical has been honored as a member of the National Biomedical Enterprise Platform! Good news: Puli Pharmaceutical has been honored as a member of the National Biomedical Enterprise Platform! On December eleven, two thousand twenty-four, the concurrent event of the two thousand twenty-four Shanghai International Biopharmaceutical Industry Week, the "Digital Yangtze River Delta, Intelligent Manufacturing for Big Health" Life and Health Industry Development Promotion Conference, was successfully held at the Guozhan Baolong Liyun Hotel in Qingpu District, Shanghai. At the conference, Puli Pharmaceutical was awarded the National Biopharmaceutical Enterprise Platform and officially became a member of the board of directors of the National Biopharmaceutical Enterprise Platform. This honor is not only a recognition of Puli Pharmaceutical's achievements in the field of biotechnology, but also an affirmation of the company's future development prospects. The National Biopharmaceutical Enterprise Platform is a biopharmaceutical enterprise innovation service platform operated by Yiyun Technology, jointly established by Shanghai Biopharmaceutical Technology Development Center, Shanghai Biopharmaceutical Industry Association, Shanghai Yangtze River Delta Science and Technology Innovation Enterprise Service Center, National Technology Transfer Eastern Center, Shanghai Financial Industry Federation, and other partners, with Shanghai Equity Custody and Trading Center as cooperative units and numerous active banks, securities firms, insurance companies, law firms, accounting firms, parks and other service institutions in the biopharmaceutical field as governing units. The platform aims to provide comprehensive financial services with strong industry characteristics for national biopharmaceutical enterprises, and create an ecosystem for the biopharmaceutical industry. The strategic emerging industries and future industries of Puli Pharmaceutical are the main battlefield for forming new quality productivity. The biopharmaceutical industry is not only an important component of the strategic emerging industries, but also a key area for future industrial layout. Under the strategic background of national industrial transformation and upgrading, Puli Pharmaceutical has proactively laid out the synthetic biology track, adopting advanced biotechnology to achieve the synthetic biology manufacturing of heavyweight weight loss and blood sugar lowering drugs such as semaglutide, the most important active ingredient of precious Tibetan medicine Rhodiola rosea, salidroside, and the only FDA approved drug for treating primary biliary cirrhosis, ursodeoxycholic acid. While conducting independent research and development, we have established long-term cooperative relationships with research institutions such as the Chinese Academy of Sciences and Zhejiang University to jointly promote the industrialization of excellent research and development achievements. Puli Pharmaceutical has won the TOPsix of the two thousand twenty-three Synthetic Biology Industry Value Gold List and is also the vice chairman unit of the "Zhejiang Synthetic Biology Industry Technology Alliance". It actively promotes technological innovation and industry university research cooperation in synthetic biology, achieving a double harvest of social and economic benefits. On the other hand, Puli Pharmaceutical is actively expanding its business in the field of innovative drugs. The two First in class innovative drugs developed by the company, namely the anti-tumor nanodrug PLATone and the dual-mode contrast agent PLtwo, have successively obtained clinical trial approvals from the US FDA and China CDE. In addition, the domestic clinical trial application for five hundred and five (b) (two) class anti-tumor boron neutron innovative drug - boron [tenB] falen for injection has also been accepted. At the same time, Puli Pharmaceutical also collaborated with innovative drug company Imunon to jointly develop a new immunotherapy for ovarian cancer, and achieved encouraging results in phase II clinical trials. In addition, Puli Pharmaceutical also collaborates with companies such as Ningdan New Drug and Nuoyu Biotechnology